Denali Therapeutics Inc. DNLI Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s net income?
- Denali Therapeutics Inc. (DNLI) reported net income of -$128.45M in Q1 2026.
- How has Denali Therapeutics Inc.'s net income changed year-over-year?
- Denali Therapeutics Inc.'s net income increased by 3.4% year-over-year, from -$132.97M to -$128.45M.
- What is the long-term trend for Denali Therapeutics Inc.'s net income?
- Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s net income has grown at a 15.2% compound annual growth rate (CAGR), from -$290.58M to -$512.54M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.